SCNX · XBRL financial data
Scienture Holdings financial statements, every fiscal year
The same tables from 8 filings, lined up. Matched by XBRL tag: renamed lines keep their history.
How these numbers work
- Every number comes from the company's XBRL financial data filed with the SEC, and each one links to its filing.
- Lines are matched by XBRL tag, so a line renamed between filings keeps its history.
- * marks a quarter worked out from the filing totals: the 10-K year minus the first three quarters, or a year-to-date total minus the earlier one. Fourth-quarter earnings per share is fourth-quarter net income over the fourth-quarter weighted shares.
- 0 means a filing states zero; a dash (—) means no filing states that number.
- “year only” means the 10-K gives the full year but not the quarters needed to work out the fourth. A worked-out quarter of revenue, cost of revenue or operating cash flow more than twice the company's largest quarter of the two years before is shown this way too.
- Gross profit is shown as the company reports it; a worked-out quarter must equal revenue less cost of revenue for that quarter, or it is a dash.
- Operating income can be above gross profit when the company books other operating income between the two, shown on its own line.
- Shares outstanding come from each filing's cover page, as of the date printed there.
- Quarters are fiscal: Q2 FY27 is the second quarter of the company's fiscal 2027.
Income statement
CSVFiscal years (SCNX's year ends in late December)
| In thousands of dollars | Dec 31, 2020 | Dec 31, 2021 | Dec 31, 2022 | †Dec 31, 2023 | †Dec 31, 2024 | Dec 31, 2025 |
|---|---|---|---|---|---|---|
| Revenue from contracts with customers | 17,123 | 9,889 | 11,448 | 8,272 | 137 | 432 |
| Cost of revenue | — | 5,143 | 5,997 | 5,674 | 131 | 100 |
| Cost of goods and services sold | 11,415 | 5,143 | 5,997 | 5,674 | 131 | 100 |
| Gross profit | 5,707 | 4,746 | 5,451 | 2,598 | 6 | 331 |
| Research and development | — | — | — | — | 2,237 | 1,956 |
| General and administrative | 7,488 | 8,812 | 1,755 | 2,786 | 6,678 | 7,926 |
| Total operating expenses | 8,214 | 10,038 | 9,876 | 9,862 | 14,707 | 42,922 |
| Operating income (loss) | (2,507) | (5,292) | (4,424) | (7,263) | (14,701) | (42,591) |
| Interest expense | 29 | 24 | 336 | 1,198 | 1,336 | 4,083 |
| Income tax expense (benefit) | — | — | — | — | (534) | (1,995) |
| Net income (loss) | (2,536) | (5,316) | (3,472) | (17,844) | 9,066 | (41,512) |
| Earnings per share, basic USD per share | — | (0.65) | (0.41) | (23.35) | 2.69 | (2.70) |
| Earnings per share, diluted USD per share | — | (0.65) | (0.41) | (7.49) | 2.48 | (2.70) |
| Weighted average shares, basic thousands of shares | — | 8,137 | 8,473 | 764 | 3,375 | 15,347 |
| Weighted average shares, diluted thousands of shares | — | — | 567 | 2,381 | 3,654 | 15,347 |
- † Share count changed about 1/7 in the period ending 2023-12-31, likely a stock split with no split ratio in the XBRL data; figures before that column are not adjusted.
- † Share count changed about 9x in the period ending 2024-12-31, likely a stock split with no split ratio in the XBRL data; figures before that column are not adjusted.
Balance sheet
CSVFiscal years (SCNX's year ends in late December)
| In thousands of dollars | Dec 31, 2020 | Dec 31, 2021 | Dec 31, 2022 | †Dec 31, 2023 | †Dec 31, 2024 | Dec 31, 2025 |
|---|---|---|---|---|---|---|
| Cash and cash equivalents | 5,920 | 3,123 | 1,134 | 152 | 308 | 6,662 |
| Accounts receivable | 805 | 979 | 729 | 822 | 11 | 731 |
| Inventory | 1,258 | 56 | 120 | 1 | — | 213 |
| Prepaid and other current assets | — | — | — | 51 | — | — |
| Total current assets | 9,221 | 4,374 | 2,093 | 2,753 | 6,305 | 7,916 |
| Property and equipment, net | 162 | 99 | 65 | 277 | 18 | 16 |
| Right-of-use asset | 387 | 1,233 | 1,052 | 530 | 201 | 23 |
| Goodwill | — | 0 | 0 | — | 21,373 | — |
| Total assets | 9,793 | 5,766 | 3,710 | 12,533 | 104,854 | 84,178 |
| Accounts payable | 257 | 477 | 729 | 2,082 | 2,899 | 1,443 |
| Accrued liabilities | 219 | 270 | 290 | 401 | 1,314 | 657 |
| Total current liabilities | 842 | 926 | 2,147 | 11,556 | 7,907 | 2,735 |
| Total deposits | — | — | — | — | — | 1,182 |
| Lease liability, non-current | 271 | 1,070 | 887 | 409 | 156 | — |
| Total liabilities | 1,114 | 1,996 | 3,367 | 11,991 | 25,782 | 14,058 |
| Accumulated deficit | (10,932) | (16,247) | (19,720) | (33,246) | (39,039) | (80,551) |
| Total stockholders' equity | 8,679 | 3,770 | 763 | 542 | 79,072 | 70,120 |
| Total liabilities and equity | 9,793 | 5,766 | 3,710 | 12,533 | 104,854 | 84,178 |
| Common shares outstanding (cover page) thousands of shares | 8,093 | 8,181 | 10,111 | 1,406 | 12,515 | 40,631 |
- † Share count changed about 1/7 in the period ending 2023-12-31, likely a stock split with no split ratio in the XBRL data; figures before that column are not adjusted.
- † Share count changed about 9x in the period ending 2024-12-31, likely a stock split with no split ratio in the XBRL data; figures before that column are not adjusted.
Cash flows
CSVFiscal years (SCNX's year ends in late December)
| In thousands of dollars | Dec 31, 2020 | Dec 31, 2021 | Dec 31, 2022 | †Dec 31, 2023 | †Dec 31, 2024 | Dec 31, 2025 |
|---|---|---|---|---|---|---|
| Net income (loss) | (2,536) | (5,316) | (3,472) | (17,844) | 9,066 | (41,512) |
| Stock-based compensation | 448 | 64 | 79 | 30 | 26 | 2,069 |
| Net cash from operating activities | (2,215) | (2,566) | (1,526) | (2,225) | (14,265) | (13,380) |
| Purchases of property and equipment | 38 | 23 | — | — | 12 | — |
| Net cash from investing activities | (38) | (23) | (428) | (276) | 27,553 | — |
| Proceeds from issuing common stock | 5,994 | — | 131 | — | 2,954 | 26,293 |
| Proceeds from issuing equity | — | — | — | — | 2,477 | — |
| Dividends paid | — | — | — | — | 14,859 | — |
| Net cash from financing activities | 5,300 | (208) | (35) | 1,406 | (12,980) | 19,734 |
| Net change in cash | 3,048 | (2,797) | (1,989) | (943) | 308 | 6,354 |
- † Share count changed about 1/7 in the period ending 2023-12-31, likely a stock split with no split ratio in the XBRL data; figures before that column are not adjusted.
- † Share count changed about 9x in the period ending 2024-12-31, likely a stock split with no split ratio in the XBRL data; figures before that column are not adjusted.
Compare with peers
SIC 2834 and related industry codes, similar size. Each row is the latest quarter reported.
How peers are chosen
- SIC 2834 and related industry codes with public float (or, where float is missing, quarterly revenue) between 0.2x and 5x the company's.
- Each row is the latest quarter the company has reported, named in the Quarter column; when that filing is a 10-K, it is the fourth quarter, never the full year.
- Runway shows only for companies burning cash with under $10B of public float.
- * marks a quarter worked out from the filing totals: for a 10-Q, the year-to-date total less the earlier one.
- A cell reading “not reported” means the filings give no figure for that quarter alone.
| Company | Cash ($K) | Revenue, quarter ($K) | Operating cash flow, quarter ($K) | Shares outstanding | Runway | Quarter |
|---|---|---|---|---|---|---|
| Scienture Holdings | 8,188 | 344 | (3,132)* | 41.1M | 2.6 quarters | 10-QJun 30, 2026 |
| Kiora Pharmaceuticals | 7,077 | not reported | (1,892)* | 4.4M | 8.9 quarters | 10-QJun 30, 2026 |
| Brainstorm Cell Therapeutics | 22 | not reported | (895) | 11.0M | 0.0 quarters | 10-QJun 30, 2026 |
| LeonaBio | 32,323 | not reported | (16,958)* | 9.4M | 3.0 quarters | 10-QJun 30, 2026 |
| Mannatech | 6,034 | 26,650 | (792)* | 1.9M | 7.6 quarters | 10-QJun 30, 2026 |
| Traws Pharma | 5,016 | not reported | (7,504)* | 15.4M | 0.7 quarters | 10-QJun 30, 2026 |
| BioCardia | 4,117 | not reported | (1,735)* | 15.1M | 2.4 quarters | 10-QJun 30, 2026 |
| Alaunos Therapeutics | 124 | 0 | (300)* | 2.5M | 0.4 quarters | 10-QJun 30, 2026 |
| Raphael Pharmaceutical | 1 | not reported | 0* | 20.2M | — | 10-QJun 30, 2026 |
Not investment advice. Not affiliated with the U.S. SEC.